Polar Capital Holdings Plc - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.

Quarter-by-quarter ownership
Polar Capital Holdings Plc ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$20,776,184
-30.1%
1,007,0860.0%0.15%
+2.7%
Q2 2023$29,719,108
+155.4%
1,007,086
+99.4%
0.15%
+97.4%
Q1 2023$11,635,200
+384.6%
505,000
+838.1%
0.08%
+744.4%
Q4 2021$2,401,000
-11.6%
53,8350.0%0.01%
-18.2%
Q3 2021$2,716,000
-29.0%
53,835
+10.3%
0.01%
-35.3%
Q2 2021$3,828,00048,7980.02%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$240,012,00028.78%
Casdin Capital, LLC 1,500,000$48,255,0002.16%
Flagship Pioneering Inc. 2,619,968$84,284,0001.98%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 38,000$8,192,0001.85%
Yiheng Capital Management, L.P. 1,014,684$32,642,0001.49%
SECTORAL ASSET MANAGEMENT INC 207,100$6,662,0001.18%
Artal Group S.A. 600,000$19,302,0000.81%
GILDER GAGNON HOWE & CO LLC 2,619,217$84,260,0000.78%
Temasek Holdings (Private) Ltd 5,369,487$172,736,3970.73%
BRANDYWINE MANAGERS, LLC 9,601$309,0000.53%
View complete list of DENALI THERAPEUTICS INC shareholders